Hemolysis

Hemolysis, also spelled haemolysis, is the destruction of red blood cells. In laboratory usage, it commonly refers to membrane rupture and the release of hemoglobin into the surrounding fluid; in clinical medicine, it also encompasses premature removal of intact or damaged red cells by phagocytic cells. Excessive destruction causes hemolytic anemia when replacement by the bone marrow cannot keep pace. Hemolysis and hemolytic anemia are therefore related but not interchangeable terms. (pubmed.ncbi.nlm.nih.gov)

Within the body, hemolysis may occur in the circulation or through clearance in organs such as the spleen and liver. Its causes include inherited red-cell abnormalities, immune reactions, infections, and mechanical injury. Outside the body, hemolysis can alter blood test results, while controlled hemolysis assays help evaluate blood-contacting medical devices. The term also describes characteristic changes around bacterial colonies on blood agar, linking its clinical meaning to laboratory medicine and microbiology. (merckmanuals.com)

Definition, normal turnover, and classification

Hemolysis has a narrow cellular meaning—disruption of the erythrocyte membrane with release of hemoglobin—and a broader clinical meaning: premature destruction of circulating red blood cells, shortening their survival. Clinical usage therefore includes both cells that rupture in the circulation and cells removed intact by tissue macrophages. Normal human erythrocytes circulate for approximately 120 days before age-related changes lead to their clearance, principally through phagocytosis. This physiological turnover is not, by itself, evidence of a hemolytic disorder; pathological hemolysis denotes accelerated loss relative to normal survival. The mechanisms that identify naturally aging cells for removal are not completely resolved. (pmc.ncbi.nlm.nih.gov)

Whether accelerated destruction produces anemia depends on the balance between red-cell loss and replacement by the bone marrow. In compensated hemolysis, increased erythrocyte production maintains the circulating hemoglobin concentration despite shortened cell survival; the expression “compensated hemolytic anemia” is also used for this state. Hemolytic anemia develops when replacement cannot keep pace with destruction. Thus, hemolysis describes a process, whereas anemia describes a resulting deficit: the two are not interchangeable. Increased marrow output commonly raises the number of circulating reticulocytes, or immature red cells, although concurrent impairment of blood-cell production can limit this response. (merckmanuals.com)

The anatomical classification distinguishes intravascular from extravascular hemolysis. Intravascular destruction occurs within blood vessels, where membrane disruption releases hemoglobin into plasma. Extravascular destruction occurs through premature removal by macrophages, particularly in the spleen and liver, without requiring prior rupture in circulating blood. These categories describe the site of destruction rather than its underlying cause, and both routes can operate in the same disorder. (pmc.ncbi.nlm.nih.gov)

A separate classification distinguishes intrinsic, or intracorpuscular, abnormalities from extrinsic, or extracorpuscular, causes. Intrinsic defects affect the red cell itself: examples include membrane abnormalities in hereditary spherocytosis, enzyme defects in glucose-6-phosphate dehydrogenase deficiency, and abnormal hemoglobin in sickle cell disease. Extrinsic causes act on red cells from outside, as with antibody-mediated destruction, mechanical injury from prosthetic heart valves, or infection. The inherited–acquired distinction is independent: intrinsic disorders are commonly inherited, but paroxysmal nocturnal hemoglobinuria is an acquired intrinsic abnormality. “Intrinsic” therefore does not mean “hereditary.” (arupconsult.com)

The temporal classification describes hemolysis as acute, chronic, or episodic. Acute hemolysis develops rapidly; chronic hemolysis persists; episodic hemolysis occurs in discrete attacks. These terms do not independently specify the site, origin, or severity of destruction. For example, an inherited enzyme deficiency can remain relatively quiet between episodes, with increased destruction following infection or exposure to particular medicines or foods. Conversely, an acquired disorder may produce persistent hemolysis. A complete description can therefore combine several labels—such as inherited, intrinsic, and episodic—rather than placing every disorder into a single exclusive category. (merckmanuals.com)

Sites of destruction and handling of released hemoglobin

In extravascular hemolysis, macrophages remove erythrocytes from the circulation, principally in the spleen and liver, and digest them by phagocytosis. Clearance depends on both the physical condition of the cell and signals on its surface: damaged or poorly deformable erythrocytes are removed, as are cells coated with IgG antibodies or components of the complement system, such as C3. The spleen can remove mildly abnormal cells, whereas severely abnormal or heavily coated cells are cleared in both organs. Thus, extravascular destruction does not require the erythrocyte to rupture freely into plasma. (merckmanuals.com)

In intravascular hemolysis, disruption of the cell membrane releases hemoglobin directly into circulating plasma. Mechanical shear, complement-mediated injury, and toxins can produce this route of destruction. Extracellular hemoglobin binds haptoglobin, forming complexes recognized by the macrophage scavenger receptor CD163. Receptor-mediated uptake directs these complexes into intracellular degradation pathways, allowing their iron to be recovered rather than lost through the kidneys. A structural study published in 2025 demonstrated how trimeric CD163 recognizes the haptoglobin–hemoglobin complex. Because haptoglobin is consumed during clearance, sustained release of hemoglobin can deplete its circulating supply. (merckmanuals.com)

Within the clearance system, hemoglobin breakdown separates iron recovery from disposal of the heme pigment. Globin undergoes protein degradation, while heme oxygenase opens the heme ring, releasing iron and carbon monoxide and producing biliverdin; biliverdin reductase subsequently forms bilirubin. Recovered iron can be retained in ferritin stores or exported through ferroportin for reutilization, including new hemoglobin synthesis in the bone marrow. The liver can expand its clearance capacity during increased erythrocyte destruction: in mouse experiments reported by Igor Theurl and colleagues in 2016, recruited monocytes ingested stressed erythrocytes and developed into transient, ferroportin-expressing hepatic macrophages. (pubmed.ncbi.nlm.nih.gov)

Newly formed bilirubin is initially unconjugated and travels to the liver bound to albumin. Hepatocytes conjugate it with glucuronic acid through the enzyme UGT1A1, producing more water-soluble bilirubin conjugates that are secreted into bile. Accelerated erythrocyte destruction therefore increases the bilirubin load reaching the liver, regardless of whether the original destruction occurred within vessels or inside macrophages. This pigment-processing pathway is distinct from the direct appearance of intact hemoglobin in urine. (ncbi.nlm.nih.gov)

When intravascular release exceeds plasma hemoglobin-binding capacity, unbound hemoglobin dimers undergo filtration by the kidneys. Proximal tubular cells reabsorb some of this filtered protein and retain iron from its breakdown as hemosiderin. Hemoglobinuria develops when the filtered load exceeds tubular reabsorptive capacity; hemosiderinuria occurs when iron-containing tubular cells are shed into urine. Consequently, substantial or persistent intravascular destruction can cause urinary iron loss, unlike the predominantly iron-conserving recycling associated with macrophage clearance. (merckmanuals.com)

Inherited red-cell abnormalities

Inherited membrane disorders impair the mechanical stability or deformability of the erythrocyte. In hereditary spherocytosis, defects in ankyrin, spectrin, band 3, or protein 4.2 weaken attachments between the cell membrane and its supporting cytoskeleton. Progressive membrane loss reduces the surface-area-to-volume ratio, producing spherical cells that deform poorly and are preferentially retained and destroyed in the spleen. Approximately 75% of cases follow autosomal dominant inheritance; recessive forms and new mutations also occur. Hereditary elliptocytosis principally involves defective interactions within the membrane skeleton, especially those involving α-spectrin, β-spectrin, and protein 4.1. Affected cells become elongated during circulation. Many affected individuals have little or no hemolysis, whereas more severe skeletal instability causes fragmentation and clinically significant hemolytic anemia. (medlineplus.gov)

Glucose-6-phosphate dehydrogenase deficiency compromises antioxidant protection rather than primarily limiting energy production. G6PD supports production of NADPH through the pentose phosphate pathway; NADPH enables regeneration of reduced glutathione, which protects hemoglobin and membrane components from oxidative damage. When this protection is insufficient, oxidized hemoglobin can precipitate as Heinz bodies, and damaged cells undergo premature destruction. The disorder is X-linked, but heterozygous females can also be affected because X-chromosome inactivation produces variable proportions of enzyme-deficient erythrocytes. Hemolysis is commonly episodic, following infection, exposure to certain oxidant medicines, or ingestion of fava beans; many affected people remain asymptomatic between episodes. (ncbi.nlm.nih.gov)

Pyruvate kinase deficiency instead impairs energy metabolism. Autosomal recessive pathogenic variants in PKLR reduce activity of an enzyme in glycolysis, decreasing production of adenosine triphosphate (ATP). ATP depletion compromises maintenance of red-cell integrity and deformability, promoting premature splenic clearance. Unlike the commonly episodic pattern of G6PD-associated hemolysis, pyruvate kinase deficiency typically produces chronic nonspherocytic hemolytic anemia. Severity ranges from compensated disease with few symptoms to severe anemia beginning in infancy; infection can intensify the underlying hemolysis. (medlineplus.gov)

Structural hemoglobin abnormalities shorten red-cell survival through different mechanisms. In sickle cell disease, deoxygenated hemoglobin S polymerizes into stiff intracellular fibers, distorting erythrocytes and reducing their flexibility. Fragile, damaged cells are destroyed prematurely; sickled erythrocytes may survive only about 10–20 days. Vascular obstruction is a related but distinct consequence of their abnormal physical properties. Unstable hemoglobins, including Hb Köln and Hb Zürich, instead undergo denaturation and precipitation. Their Heinz-body inclusions bind to the red-cell membrane and promote splenic destruction. Most unstable hemoglobin disorders are autosomal dominant, although new variants and other inheritance patterns occur. (nhlbi.nih.gov)

Thalassemias involve reduced synthesis of α- or β-globin chains rather than simply an altered hemoglobin structure. The resulting imbalance leaves excess unmatched chains that damage developing and circulating red cells. In β-thalassemia, excess α-globin forms aggregates that generate oxidative stress, impair erythroid differentiation, and promote premature death of precursors in the bone marrow. This ineffective erythropoiesis is distinct from peripheral hemolysis: it reduces the number of mature erythrocytes reaching the circulation, while hemolysis shortens the survival of those that do. Both mechanisms contribute to anemia, but ineffective erythropoiesis is a major driver in severe β-thalassemia. Consequently, increased marrow erythroid activity does not necessarily produce an adequate circulating red-cell output. (ncbi.nlm.nih.gov)

Immune-mediated destruction

In warm autoimmune hemolytic anemia, autoantibodies—usually immunoglobulin G (IgG)—bind red-cell surface antigens most effectively near $37\,^\circ\mathrm{C}$. Splenic macrophages recognize the exposed Fc portions of cell-bound IgG and either engulf the erythrocyte or remove part of its membrane. Partial membrane removal produces spherocytes: rounded cells with reduced deformability that are subsequently trapped and destroyed in the spleen. Destruction is therefore predominantly extravascular rather than direct antibody-induced membrane rupture. Approximately one-third of patients also have complement attached to their erythrocytes; C3b-coated cells can be cleared by hepatic macrophages. Warm autoimmune hemolytic anemia may occur without an identifiable associated disorder or accompany systemic lupus erythematosus and lymphoproliferative disorders such as chronic lymphocytic leukemia. (ashpublications.org)

In cold agglutinin disease, the pathogenic antibody is usually monoclonal IgM, commonly directed against the erythrocyte I antigen. Binding in cooler peripheral circulation causes agglutination and activates the classical complement pathway. On rewarming, IgM can detach while complement fragments remain on the cells. C3b-mediated clearance, principally in the liver, accounts for much of the hemolysis; activation of terminal complement can additionally produce intravascular lysis, particularly during exacerbations. Thus, “cold” does not mean that destruction occurs exclusively outside the body’s warmer central circulation. Clinical significance depends strongly on the antibody’s thermal amplitude—the highest temperature at which it reacts—not simply its concentration. Primary cold agglutinin disease is associated with a clonal marrow B-cell population; secondary cold agglutinin syndrome can accompany infections such as Mycoplasma pneumoniae infection or infectious mononucleosis, or an overt lymphoma. (ashpublications.org)

Paroxysmal cold hemoglobinuria has a different cold-reactive mechanism. Its characteristic Donath–Landsteiner antibody, identified by Julius Donath and Karl Landsteiner in 1904, is usually an IgG autoantibody against the P antigen. It acts as a biphasic hemolysin: antibody binding and initial complement fixation occur at low temperature, whereas subsequent warming permits complement-mediated intravascular lysis. The resulting release of hemoglobin can cause hemoglobinuria. Unlike the usual IgM-mediated process in cold agglutinin disease, this is an IgG-mediated, predominantly intravascular disorder. It is now encountered especially as an acute illness in children following viral infection and is often self-limited, although anemia can develop rapidly and become severe. (ashpublications.org)

Alloimmune hemolysis targets red-cell antigens belonging to another individual rather than the patient’s own cells. In an incompatible transfusion, recipient antibodies recognize donor erythrocytes. Incompatibility in the ABO blood group system can cause an acute intravascular hemolytic reaction, often beginning during or shortly after transfusion. Delayed reactions instead arise when previous exposure through transfusion or pregnancy has established immune memory: antibodies that were initially undetectable increase after renewed antigen exposure, shortening donor-cell survival over subsequent days. In hemolytic disease of the fetus and newborn, maternal IgG crosses the placenta and attacks fetal erythrocytes bearing a corresponding antigen, such as Rh D. Maternal IgM does not cross the placenta. ABO-associated neonatal hemolysis also occurs and is generally less severe than Rh-associated disease. (msdmanuals.com)

Drug-induced immune hemolysis includes drug-dependent antibody reactions and drug-independent autoantibody formation. In the classic penicillin-associated mechanism, drug bound to the erythrocyte membrane provides a target for antibody binding; other drug-dependent reactions require soluble drug or its metabolites. Methyldopa can instead induce erythrocyte autoantibodies resembling those of warm autoimmune hemolytic anemia. Implicated antibiotics include ceftriaxone and piperacillin, and complement activation can produce severe intravascular destruction. These immune mechanisms are distinct from nonimmune drug-related injury, such as oxidant damage in susceptible erythrocytes. (pmc.ncbi.nlm.nih.gov)

Acquired nonimmune injury and complement susceptibility

Mechanical injury destroys erythrocytes when abnormal flow imposes excessive shear stress on their membranes. Prosthetic heart valves can generate damaging jets, particularly around a paravalvular leak; extracorporeal circuits and blood pumps can likewise expose circulating cells to nonphysiological stresses. Fragmentation produces irregular red-cell remnants called schistocytes. In device-associated hemolysis, the injurious flow originates at a particular valve or circuit component, although its effects are detectable throughout the circulation. This differs from thrombotic microangiopathy, in which small-vessel endothelial injury and microvascular thrombosis create numerous sites of red-cell damage, often accompanied by platelet consumption and ischemic organ injury. (merckmanuals.com)

Several clinically distinct disorders produce this fragmentation pattern. Thrombotic thrombocytopenic purpura (TTP) involves severely reduced activity of ADAMTS13, the enzyme that cleaves von Willebrand factor; persistence of unusually large multimers promotes platelet-rich microthrombi. Acquired TTP commonly results from antibodies against ADAMTS13, but erythrocyte destruction is mechanical rather than caused by antibodies directed against red-cell antigens. Shiga toxin-associated hemolytic uremic syndrome (HUS), commonly following infection with toxin-producing Escherichia coli, combines microangiopathic hemolysis, thrombocytopenia, and acute kidney injury; complement-mediated HUS represents a distinct mechanism. Disseminated intravascular coagulation causes widespread coagulation activation and consumption of platelets and clotting factors, often in settings such as sepsis or major trauma. HELLP syndrome—hemolysis, elevated liver enzymes, and low platelets—is a pregnancy-associated disorder. These conditions share red-cell fragmentation but are not interchangeable diagnoses. (nhlbi.nih.gov)

Infection can injure erythrocytes through intracellular parasitism or extracellular toxins. Plasmodium species, responsible for malaria, and Babesia species invade red cells and cause their destruction; Babesia microti is the most frequently identified cause of human babesiosis in the United States. By contrast, Clostridium perfringens need not invade erythrocytes to damage them. Its alpha toxin has phospholipase C activity and disrupts membrane phospholipids, providing a mechanism for toxin-mediated hemolysis. Experimental work has shown that the toxin’s membrane-binding region is essential to its hemolytic activity, distinguishing membrane injury from the mere presence of a circulating organism. (merckmanuals.com)

Chemical and physical exposures provide additional nonimmune mechanisms. Oxidants such as dapsone, phenazopyridine, and naphthalene can damage hemoglobin and red-cell membranes. Oxidized, denatured hemoglobin may aggregate into Heinz bodies, while membrane damage reduces deformability and shortens cell survival. Inherited glucose-6-phosphate dehydrogenase deficiency increases susceptibility to such acquired oxidative challenges; the exposure and the underlying susceptibility are therefore separate causal elements. Severe burns can directly injure erythrocytes thermally. Other recognized causes include copper toxicity, lead, and certain insect or snake venoms, whose mechanisms differ from antibody-mediated destruction. (merckmanuals.com)

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired intrinsic susceptibility rather than an external mechanical injury or an autoimmune attack on erythrocytes. In almost all cases, a somatic mutation in PIGA arises in a hematopoietic stem cell, generating a clone of blood cells deficient in glycosylphosphatidylinositol (GPI)-anchored surface proteins. These include CD55 and CD59, which normally restrain the complement system. CD55 accelerates complement-convertase decay, whereas CD59 inhibits formation of the membrane attack complex. Their deficiency leaves affected erythrocytes vulnerable to complement-mediated intravascular lysis without requiring a red-cell-directed autoantibody. Because the mutation occurs in a blood-forming stem cell rather than exclusively in mature erythrocytes, other blood-cell lineages can share the surface-protein deficiency. (medlineplus.gov)

Clinical manifestations and consequences

Fatigue, weakness, reduced exercise tolerance, and breathlessness principally reflect the anemia that develops when red-cell destruction exceeds replacement. Reduced circulating hemoglobin lowers the blood’s oxygen-carrying capacity; tachycardia and palpitations accompany the circulatory response to this deficit. Pallor and dizziness may also occur. These manifestations are not specific to hemolysis: they occur in anemia from other causes and do not, by themselves, establish accelerated red-cell destruction. (arupconsult.com)

Clinical severity depends on both the rate of destruction and the response of the bone marrow. Increased red-cell production may maintain hemoglobin despite shortened cell survival, producing compensated hemolysis with few or no symptoms. Mild hemolytic anemia can likewise be asymptomatic. In contrast, rapidly developing destruction may outpace marrow replacement and produce marked weakness, breathlessness, and tachycardia over a short interval. Impaired marrow production can further limit compensation, so the intensity of symptoms does not depend on the destructive process alone. Slowly developing disease and abrupt hemolytic episodes therefore have substantially different presentations. (merckmanuals.com)

Jaundice and dark urine are associated more directly with red-cell breakdown than with the oxygen deficit of anemia. Yellow discoloration of the sclerae and skin develops when increased production of bilirubin from hemoglobin breakdown exceeds hepatic processing capacity. Substantial intravascular destruction may produce red-brown urine through the urinary passage of free hemoglobin, termed hemoglobinuria. This is distinct from hematuria, in which urine contains intact red cells. Hemoglobinuria is not a universal feature of hemolysis, particularly when destruction occurs predominantly outside the circulation. (merckmanuals.com)

Chronic hemolytic disorders may be accompanied by enlargement of the spleen, liver, or both, although hepatosplenomegaly is not present in every disorder. Increased splenic clearance contributes particularly to splenic enlargement in some forms of extravascular hemolysis; an enlarged spleen may itself sequester additional red cells. Sustained bilirubin production also favors pigment gallstones. These may remain clinically silent or cause biliary symptoms; migration into the common bile duct can produce obstruction and additional jaundice. Organ enlargement and biliary complications therefore vary with the underlying disease and duration of hemolysis rather than constituting obligatory findings. (merckmanuals.com)

Severe, persistent anemia can have cardiovascular consequences, including cardiac enlargement, arrhythmias, and heart failure. A separate complication is thrombosis, documented in particular autoimmune hemolytic disorders rather than uniformly across all causes. In a 2018 retrospective study by Sylvain Audia and colleagues, 11 of 48 patients with warm autoimmune hemolytic anemia—23%—experienced venous thromboembolism, including deep-vein thrombosis and pulmonary embolism; 10 of those 11 experienced an event during active disease. This was a selected clinical cohort, not an estimate applicable to every person with hemolysis. Proposed contributors include inflammatory and coagulation activation and the effects of free hemoglobin on nitric-oxide availability, but the thrombotic process is multifactorial. (nhlbi.nih.gov)

Laboratory recognition and identification of the cause

Laboratory recognition depends on a combined pattern rather than a single abnormal result. The complete blood count establishes whether anemia is present and identifies associated platelet or leukocyte abnormalities. Increased reticulocytes indicate a compensatory bone marrow response, while increased lactate dehydrogenase (LDH), increased unconjugated bilirubin, and decreased haptoglobin support accelerated red-cell destruction. Reticulocytosis may be absent when iron deficiency or marrow suppression limits replacement. Thus, a normal reticulocyte count does not necessarily exclude hemolysis. (arupconsult.com) Haptoglobin falls as circulating hemoglobin–haptoglobin complexes are cleared, but severe liver disease can also lower its concentration; conversely, its rise during inflammation can complicate interpretation. These results therefore require comparison with the clinical setting and other laboratory findings. (prd1.mayocliniclabs.com)

The peripheral blood smear helps direct subsequent testing, but most morphological findings are not independently diagnostic. Spherocytes suggest hereditary spherocytosis or immune-mediated destruction; schistocytes indicate fragmentation, including injury associated with mechanical valves or thrombotic microangiopathy. Sickled cells suggest a hemoglobin disorder, while Heinz bodies point toward oxidant injury, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or unstable hemoglobins. (arupconsult.com) Heinz bodies are precipitates of denatured hemoglobin demonstrated using a supravital stain rather than reliably identified on a routine stained film. (aafp.org) Urinalysis distinguishes hemoglobinuria from hematuria: a positive dipstick reaction for heme with few or no intact erythrocytes supports pigmenturia rather than bleeding. Because myoglobin also produces a positive heme reaction, this finding requires correlation with evidence of red-cell destruction. (merckmanuals.com)

The direct antiglobulin test (DAT, or direct Coombs test) detects immunoglobulin or complement attached to circulating red cells. Polyspecific testing is commonly followed by separate testing for IgG and C3 to characterize the coating. A positive DAT establishes sensitization, not active destruction: positivity can occur without hemolysis, including after certain medicines or passive antibody exposure. Conversely, immune hemolysis can have a negative routine DAT when antibody density is below the assay’s detection threshold, low-affinity antibodies are removed during washing, or the coating immunoglobulin is not recognized by the reagent. More sensitive or differently configured assays can identify some such cases. (merckmanuals.com)

Cause-specific investigations include quantitative red-cell enzyme assays, particularly for G6PD and pyruvate kinase. Interpretation depends on the age distribution of circulating cells and any recent transfusion. During or shortly after a G6PD-related episode, preferential destruction of deficient older cells and enrichment with younger cells can produce an apparently normal activity result; reticulocytosis itself can raise measured activity. Transfused donor erythrocytes may likewise mask the patient’s intrinsic deficiency. (prd1.mayocliniclabs.com) Hemoglobin analysis uses high-performance liquid chromatography, electrophoresis, or complementary separation methods to identify and quantify variants. Recent transfusion can introduce donor hemoglobins or dilute the patient’s abnormal fractions, making the transfusion history essential to interpretation. (arupconsult.com)

Membrane investigations include eosin-5′-maleimide binding, osmotic fragility testing, and osmotic-gradient ektacytometry. Reduced dye binding supports hereditary spherocytosis, whereas fragility and deformability measurements examine different consequences of membrane abnormalities. (pmc.ncbi.nlm.nih.gov) Suspected paroxysmal nocturnal hemoglobinuria is investigated by flow cytometry: CD59 expression characterizes affected erythrocytes, while fluorescent aerolysin (FLAER) and accompanying markers identify deficient granulocytes and monocytes. Leukocyte analysis provides an assessment not dependent on the survival of affected red cells. (media.versiti.org) Targeted DNA sequencing or hereditary-anemia panels can resolve overlapping phenotypes and confirm enzyme or membrane disorders; examples include analysis of G6PD, PKLR, ANK1, and SPTB. Molecular findings are interpreted alongside the biochemical and cellular phenotype. (arupconsult.com)

Established approaches to clinical management

Management separates two objectives: correcting anemia and reducing the process that shortens red-cell survival. Mild, compensated hemolysis may require observation rather than active treatment, whereas rapidly progressive anemia may require transfusion support alongside cause-directed therapy. Transfused erythrocytes restore circulating oxygen-carrying capacity but do not, by themselves, stop immune attack or another continuing destructive process. Treatment of an underlying infection or associated disorder, and withdrawal of an implicated medicine, can remove a precipitating cause rather than merely replace destroyed cells. (nhlbi.nih.gov)

Blood transfusion has an important supportive role when anemia is severe or develops rapidly. In immune hemolysis, autoantibodies can complicate compatibility testing; transfusion services distinguish these reactions from clinically significant antibodies against donor-cell antigens. Life-threatening anemia may necessitate transfusion before complete serological compatibility can be established. In cold-antibody disorders, transfusion practice also includes measures to maintain warmth, including blood-warming equipment. These interventions address the immediate consequences of anemia while treatment directed at red-cell destruction takes effect. (merckmanuals.com)

For warm autoimmune hemolytic anemia, glucocorticoids such as prednisone are established initial treatment. Rituximab, an anti-CD20 monoclonal antibody, is used in relapsing or refractory disease and may be combined with glucocorticoids initially. A 2013 randomized trial involving 64 newly diagnosed patients reported a satisfactory response at 12 months in 75% receiving rituximab plus prednisolone, compared with 36% receiving prednisolone alone. Other immune-directed medicines include mycophenolate mofetil and azathioprine. Splenectomy remains an option in selected cases because the spleen is an important site of antibody-coated red-cell clearance; it is not a universal treatment for immune hemolysis. (pubmed.ncbi.nlm.nih.gov)

Cold agglutinin disease requires a different approach: glucocorticoids have limited effectiveness, and splenectomy is generally ineffective. Established treatments include rituximab, sometimes combined with bendamustine, and inhibition of the complement system. Sutimlimab targets C1s, interrupting the classical complement pathway responsible for much of the red-cell destruction. The US Food and Drug Administration approved it in 2022 to reduce transfusion requirements attributable to hemolysis in adults with cold agglutinin disease. Complement inhibition does not remove the underlying antibody-producing cells and may not resolve cold-induced circulatory symptoms. (merckmanuals.com)

Paroxysmal cold hemoglobinuria is also managed differently from warm autoimmune disease. Supportive care, avoidance of cold exposure, and treatment of an associated infection are central; childhood episodes often resolve spontaneously. Evidence for glucocorticoids is less secure than in warm autoimmune hemolytic anemia, and splenectomy has no established value. In drug-induced immune hemolysis, discontinuing the causative medicine is a central intervention rather than assuming that prolonged immunosuppression is necessary. (merckmanuals.com)

Selected inherited disorders, including sickle cell disease and severe thalassemia, may be treated with hematopoietic stem-cell transplantation. Donor-derived blood-forming stem cells establish a new source of erythrocytes, making transplantation potentially curative rather than simply supportive. Unlike transfusion, it changes the continuing production of abnormal cells. Its use is restricted by disease-specific eligibility, donor availability, and risks such as graft-versus-host disease, serious infection, and graft failure. (nhlbi.nih.gov)

Hemolysis in collected blood specimens

Hemolysis detected in a blood tube may have occurred in vivo, before collection, or in vitro, during collection, transport, processing, or storage. In-vitro hemolysis is a preanalytical specimen-quality problem: mechanical stress during difficult collection, excessive agitation, or unsuitable handling can disrupt erythrocytes after blood has left the circulation. Transport systems can also contribute, although their effects depend on the installation and operating conditions. Consequently, a laboratory designation of “hemolyzed specimen” describes the sample, not a diagnosis of hemolytic anemia. Establishing destruction within the patient requires clinical and laboratory evidence beyond the appearance of one tube. (pmc.ncbi.nlm.nih.gov)

Several mechanisms alter blood-test results. First, ruptured cells release constituents whose intracellular concentrations or activities exceed those in plasma. Potassium and lactate dehydrogenase (LDH) are important examples: their measured values can increase after collection without corresponding changes in the patient. Second, free hemoglobin absorbs light and can overlap the wavelengths used in photometric assays. Third, hemoglobin and other released components can participate in, accelerate, or inhibit assay reactions; hemoglobin-associated oxidative degradation of bilirubin can produce falsely decreased bilirubin measurements in susceptible methods. Finally, release of intracellular fluid changes the specimen’s composition and can dilute constituents present at lower concentrations inside erythrocytes. The resulting bias therefore need not be upward, and its magnitude depends on the assay, analyte concentration, and degree of hemolysis. (pmc.ncbi.nlm.nih.gov)

After centrifugation, free hemoglobin commonly gives serum or plasma a pink-to-red appearance. Visual inspection against a white background or reference palette provides a rapid estimate, but is subjective and poorly standardized; other pigments or turbidity complicate interpretation. The CDC’s reference palette, described in 2024, identifies $100\ \mathrm{mg/dL}$ hemoglobin as a rejection level for the serologic testing addressed by that resource—not as a universal cutoff for every laboratory assay. Automated hemolysis indices use spectrophotometric measurements to estimate free hemoglobin, expressed as numerical values or semiquantitative categories. These indices are not interchangeable across analyzer platforms and do not distinguish in-vivo from in-vitro destruction. Red discoloration is not specific to hemoglobin: in experiments published online in 2016, Laura Fueyo and colleagues showed that hydroxocobalamin, an intensely red cyanide antidote, increased the measured hemolysis index in spiked plasma. (cdc.gov)

Interference limits are therefore assay-specific rather than properties of the specimen alone. A 2021 investigation of 35 Abbott Alinity chemistry assays found significant hemolysis interference in 12 under the study’s acceptance criteria. Potassium and LDH increased, whereas enzymatic creatinine and direct bilirubin decreased; some effects differed between low and high analyte concentrations. Laboratory reporting policies use manufacturer interference claims and local verification to determine whether an individual result is released, annotated, or withheld pending another specimen. An affected potassium measurement does not automatically invalidate every other measurement from the same tube. Conversely, a mildly discolored specimen can exceed the interference limit of a particularly sensitive assay. (pmc.ncbi.nlm.nih.gov)

Specimen-quality monitoring uses hemolysis rates and index distributions to identify problems in collection or transport rather than attributing every event to disease. The need for local assessment is illustrated by differing transport studies: a 2014 investigation found greater hemolysis with its pneumatic-tube system, whereas a 2016 emergency-department study found no significant difference between pneumatic transport and hand delivery—13.6% versus 13.1%, respectively. Tracking specimen rejection, recollection, and transport-associated changes allows laboratories to evaluate particular workflows without treating all pneumatic systems, or all hemolyzed results, as equivalent. (pmc.ncbi.nlm.nih.gov)

Experimental assays and blood-contacting devices

Controlled hemolysis assays measure the release of hemoglobin from erythrocytes exposed to a material or mechanical stress under defined laboratory conditions. After exposure, intact cells are separated by centrifugation, and free hemoglobin in the supernatant is quantified, commonly by spectrophotometry. Results are expressed relative to the blood’s total hemoglobin or an assay-defined reference, with background release assessed using blanks and negative controls. Positive controls demonstrate that the assay can detect erythrocyte injury. These measurements characterize acute damage under experimental conditions; they are not, by themselves, a clinical diagnosis of hemolytic disease. (pmc.ncbi.nlm.nih.gov)

Material-mediated testing distinguishes direct contact from extract exposure. In direct-contact testing, the material is incubated with blood; in extract testing, blood is exposed to fluid previously used to extract substances from the material. ASTM F756-17, recognized by the US Food and Drug Administration (FDA) in 2018, specifies static testing by these approaches and recommends both unless the application or contact duration justifies omitting one. Catheter materials and other blood-contacting components are examples of test articles. Material testing addresses one aspect of biocompatibility, rather than establishing the safety of an entire device under operating conditions; ASTM explicitly notes that the method may not predict events in every implant application. (accessdata.fda.gov)

Control selection and incubation conditions can materially affect the result. In a 2023 FDA study, Richard Malinauskas, Cindy Liu, Shelby Skoog, and Qijin Lu tested candidate controls with diluted rabbit blood pooled from three donors. Samples were incubated at $37\,^\circ\mathrm{C}$ for up to three hours. High-density polyethylene produced less than 1% mean hemolysis, whereas nitrile gloves produced approximately 5–89%, depending on brand; latex and Buna-N rubber produced approximately 4–7%. Reducing the test volume from 8 to 2 mL while proportionally reducing material size did not significantly alter results in that experiment. Hemolysis increased with incubation time, demonstrating why exposure duration and material-to-fluid ratios belong to the experimental design, rather than being interchangeable procedural details. (fda.gov)

Dynamic testing examines mechanical injury during circulation through blood pumps and extracorporeal devices. Unlike static material exposure, these experiments assess damage associated with flow-induced stresses in an operating circuit. Standardized loop configurations and controlled operating conditions allow device comparisons, while repeated plasma-free-hemoglobin measurements track accumulated damage. For example, FDA guidance for cardiopulmonary bypass oxygenators describes six-hour blood-damage testing and paired comparison of test and predicate oxygenators using identical circuits supplied from the same blood pool. Such pairing helps separate device-associated differences from variation in the blood itself. (fda.gov)

The reservoir and other supporting components can themselves affect reproducibility. In 2023, the FDA published a reusable reservoir design comprising a three-dimensionally printed base, clamps, and a blood-compatible bag, previously described in a 2017 publication. It was developed to improve mixing and air evacuation while reducing bubble entrainment and inlet collapse, and was used in testing benchmark nozzles and prototype rotary pumps. Inadequate mixing can compromise representative sampling, while entrained air introduces an additional source of blood injury. The FDA limits the reservoir tool’s validation to that component: its performance does not validate an entire circulation loop. Similarly, lower hemolysis in a comparative bench experiment establishes performance under the tested conditions, not demonstrated improvement in clinical outcomes. (cdrh-rst.fda.gov)

Hemolysis in bacterial culture

Blood agar is an enriched culture medium containing whole blood, commonly 5% sheep blood, in a nutrient agar base. It supports bacterial growth while allowing changes in the blood surrounding colonies to be observed. In diagnostic microbiology, these changes help characterize an isolate: the blood supplies erythrocytes whose destruction or discoloration produces a visible reaction in the medium. The resulting “hemolysis pattern” is a culture characteristic, rather than a measurement of red-cell destruction in the person from whom the specimen originated. (reach.cdc.gov)

Three conventional categories describe the appearance. Beta hemolysis is a clear zone around colonies, indicating extensive destruction of erythrocytes in that area; Streptococcus pyogenes, or group A streptococcus, characteristically produces this reaction. Alpha hemolysis is greenish discoloration around colonies rather than complete clearing. Gamma hemolysis denotes no visible hemolysis or associated discoloration: despite its name, it is the absence of a hemolytic reaction, not a third mechanism of erythrocyte destruction. These categories describe what is visible on the plate and do not, by themselves, identify a bacterial species. (reach.cdc.gov)

Alpha hemolysis is often described conventionally as “partial hemolysis,” but the discoloration need not represent partial membrane rupture. A 2020 experimental study of Streptococcus pneumoniae showed that bacterial hydrogen peroxide oxidized oxygenated hemoglobin to methemoglobin, changing heme iron from the ferrous to the ferric state. Mutants lacking pneumolysin, a hemolytic protein, still produced the alpha-hemolytic halo, whereas peroxide production was responsible for the characteristic appearance under aerobic conditions. Thus, in pneumococcal cultures, the greenish zone principally reflects a chemical oxidation of hemoglobin rather than direct evidence of lysis by pneumolysin. (pubmed.ncbi.nlm.nih.gov)

Streptococcal identification illustrates how the pattern guides, but does not complete, laboratory identification. Alpha-hemolytic colonies may represent S. pneumoniae or other streptococci with similar appearances. CDC identification schemes combine the plate reaction with Gram-stain morphology, catalase testing, optochin susceptibility, and, where required, bile solubility. Pneumococci are typically optochin susceptible and bile soluble, whereas other alpha-hemolytic streptococci generally lack this combination; optochin-resistant pneumococci require additional differentiation. Hemolysis therefore determines an initial investigative branch rather than establishing species identity independently. (stacks.cdc.gov)

The blood source and incubation conditions can change the recorded category. In a 2004 study by Joseph Papaparaskevas and colleagues, 72 environmental Bacillus isolates were compared on human, sheep, and horse blood agar. After 24 hours, beta hemolysis occurred in 84.7%, 70.8%, and 86.1% of isolates, respectively; after 48 hours, the corresponding proportions were 94.4%, 87.5%, and 95.8%. The same collection therefore appeared less frequently beta-hemolytic on sheep blood, and more frequently beta-hemolytic after longer incubation. Oxygen availability also affects the chemistry underlying some reactions, as demonstrated by peroxide-dependent pneumococcal alpha hemolysis under aerobic conditions. A plate result must consequently be interpreted with its medium and incubation conditions specified; it does not establish whether an infected patient has hemolytic anemia. (wwwnc.cdc.gov)

References

1. How Do Red Blood Cells Die?pmc.ncbi.nlm.nih.gov
2. Overview of Hemolytic Anemia - Hematology - Merck Manual Professional Editionmerckmanuals.com
3. Hemolytic Anemias | Choose the Right Testarupconsult.com
4. Anemia - Hemolytic Anemia | NHLBI, NIHnhlbi.nih.gov
5. Overview of Hemolytic Anemia - Merck Manual Professional Editionmerckmanuals.com
6. Structural elucidation of the haptoglobin–hemoglobin clearance mechanism by macrophage scavenger receptor CD163journals.plos.org
7. The binding sites on human heme oxygenase-1 for cytochrome p450 reductase and biliverdin reductasepubmed.ncbi.nlm.nih.gov
8. Iron transport proteins: Gateways of cellular and systemic iron homeostasispmc.ncbi.nlm.nih.gov
9. On-demand erythrocyte disposal and iron recycling requires transient macrophages in the livernature.com
10. Unconjugated Hyperbilirubinemia - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
11. Hereditary spherocytosismedlineplus.gov
12. Red blood cell vesiculation in hereditary hemolytic anemiapmc.ncbi.nlm.nih.gov
13. Hereditary Elliptocytosisncbi.nlm.nih.gov
14. Glucose-6-Phosphate Dehydrogenase Deficiencyncbi.nlm.nih.gov
15. Glucose-6-phosphate dehydrogenase deficiency: MedlinePlus Geneticsmedlineplus.gov
16. Pyruvate kinase deficiency: MedlinePlus Geneticsmedlineplus.gov
17. Pyruvate Kinase Deficiencyncbi.nlm.nih.gov
18. Sickle Cell Disease - Causes and Risk Factorsnhlbi.nih.gov
19. Unstable Hemoglobinopathiesarupconsult.com
20. GENETIC BASIS, PATHOPHYSIOLOGY, AND DIAGNOSIS - Guidelines for the Management of Transfusion-Dependent β-Thalassaemia (TDT)ncbi.nlm.nih.gov
21. Autoimmune Hemolytic Anemiamerckmanuals.com
22. Complications of Transfusionmsdmanuals.com
23. Noninfectious Complications of Blood Transfusionpubmed.ncbi.nlm.nih.gov
24. Perinatal Anemiamerckmanuals.com
25. Ceftriaxone-Induced Immune Hemolytic Anemiapmc.ncbi.nlm.nih.gov
26. Immune hemolytic anemia caused by drugspubmed.ncbi.nlm.nih.gov
27. Microangiopathic Hemolytic Anemiamerckmanuals.com
28. Hemolysis Dataset for Validating Computational Fluid Dynamic (CFD) Simulation Through Generalized Cardiovascular Medical Device Geometriescdrh-rst.fda.gov
29. Platelet Disorders—Thrombotic Thrombocytopenic Purpura (TTP)nhlbi.nih.gov
30. Infection-related hemolytic uremic syndromencbi.nlm.nih.gov
31. Babesiosiscdc.gov
32. Role of the C-domain in the biological activities of Clostridium perfringens alpha-toxinpubmed.ncbi.nlm.nih.gov
33. Differences in the Carboxy-Terminal (Putative Phospholipid Binding) Domains of Clostridium perfringens and Clostridium bifermentans Phospholipases C Influence the Hemolytic and Lethal Properties of These Enzymespmc.ncbi.nlm.nih.gov
34. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiencymerckmanuals.com
35. Deficiency of G6PD impairs the process of detoxification of free radicals and peroxides formed within the celllearning.medicine.wsu.edu
36. Paroxysmal nocturnal hemoglobinuria: MedlinePlus Geneticsmedlineplus.gov
37. PIGA gene: MedlinePlus Geneticsmedlineplus.gov
38. Venous thromboembolic events during warm autoimmune hemolytic anemia - PMCpmc.ncbi.nlm.nih.gov
39. Hemolytic Anemia: Evaluation and Differential Diagnosisaafp.org
40. Autoimmune Hemolytic Anemia - Merck Manual Professional Editionmerckmanuals.com
41. Hemoglobinopathies | Choose the Right Testarupconsult.com
42. Flow Cytometric Eosin-5′-Maleimide Test is a Sensitive Screen for Hereditary Spherocytosispmc.ncbi.nlm.nih.gov
43. Paroxysmal Nocturnal Hemoglobinuria (PNH) Test Descriptionmedia.versiti.org
44. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemiapubmed.ncbi.nlm.nih.gov
45. FDA approves treatment for adults with rare type of anemiafda.gov
46. Sutimlimab chemistry reviewaccessdata.fda.gov
47. Sickle Cell Disease - Treatmentnhlbi.nih.gov
48. Thalassemia - Treatmentnhlbi.nih.gov
49. Hemolysis associated with pneumatic tube system transport for blood samplespmc.ncbi.nlm.nih.gov
50. Does Pneumatic Tube System Transport Contribute to Hemolysis in ED Blood Samples?pubmed.ncbi.nlm.nih.gov
51. Hemolysis interference on clinical chemistry tests analyzed on DxC 700 AU (Beckman Coulter®) and kaliemia rendering algorithmpubmed.ncbi.nlm.nih.gov
52. The Impact of Hemolysis-Index Thresholds on Plasma and Serum Potassium Measurementspmc.ncbi.nlm.nih.gov
53. Optimization of hemolysis, icterus and lipemia interference thresholds for 35 clinical chemistry assayspmc.ncbi.nlm.nih.gov
54. Reference Tool to Determine Hemolysis Statuscdc.gov
55. Hemolysis index to detect degree of hydroxocobalamin interference with common laboratory testspmc.ncbi.nlm.nih.gov
56. Method for Analysis of Nanoparticle Hemolytic Properties In Vitropmc.ncbi.nlm.nih.gov
57. Recognized Consensus Standards: Medical Devices—ASTM F756-17accessdata.fda.gov
58. Effect of Test Parameters on Material-mediated Hemolysis Using the ASTM F756-17 Standard Test Methodfda.gov
59. F756 Standard Practice for Assessment of Hemolytic Properties of Materialsstore.astm.org
60. Cardiopulmonary Bypass Oxygenators 510(k) Submissions—Final Guidance for Industry and FDA Stafffda.gov
61. A Reusable, Compliant, Small Volume Blood Reservoir For In Vitro Hemolysis Testingcdrh-rst.fda.gov
62. Basic Culture Media and Isolation Techniques Glossaryreach.cdc.gov
63. Clinical Considerations for Group A Streptococcuscdc.gov
64. Laboratory Methods for the Diagnosis of Meningitisstacks.cdc.gov
65. StrepLab-Carriage Protocolcdc.gov
66. Hydrogen Peroxide Production by Streptococcus pneumoniae Results in Alpha-hemolysis by Oxidation of Oxy-hemoglobin to Met-hemoglobinpubmed.ncbi.nlm.nih.gov
67. Table — Ruling Out Bacillus anthraciswwwnc.cdc.gov